Volume 11, Issue 3 (2023)
Health Educ Health Promot 2023, 11(3): 341-348 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yousif M, Al-Jumeily D, Al-Amran F, Sadeq A, Rawaf S. Effect of COVID-19 Vaccines on Hair Loss. Health Educ Health Promot 2023; 11 (3) :341-348
URL: http://hehp.modares.ac.ir/article-5-68676-en.html
URL: http://hehp.modares.ac.ir/article-5-68676-en.html
1- Biology Department, College of Science, University of Al-Qadisiyah, Al-Qadisiyah, Iraq
2- Department of Artificial Intelligence, Faculty of Engineering and Technology, John Moores University, Liverpool, UK
3- Cardiovascular Department, College of Medicine, Kufa University, Al-Najaf, Iraq
4- Department of Obstetrics and Gynecology, College of Medicine, Kufa University, Al-Najaf, Iraq
5- WHO Collaboration Center, Imperial College, London, UK
2- Department of Artificial Intelligence, Faculty of Engineering and Technology, John Moores University, Liverpool, UK
3- Cardiovascular Department, College of Medicine, Kufa University, Al-Najaf, Iraq
4- Department of Obstetrics and Gynecology, College of Medicine, Kufa University, Al-Najaf, Iraq
5- WHO Collaboration Center, Imperial College, London, UK
Abstract: (857 Views)
Aims: The COVID-19 pandemic has led to the global distribution of vaccines, but there are concerns regarding potential side effects. Hair loss is one of the less commonly reported side effects. The present study aimed to investigate the effect of COVID-19 vaccinations on hair loss.
Instruments & Methods: A cross-sectional descriptive study was conducted with 580 participants aged between 20 to 72 years, consisting of 270 males and 310 females. Machine learning techniques were employed to analyze the data and determine any potential relationship between COVID-19 vaccines and hair loss. A logistic regression analysis was used to assess the odds ratio and 95% confidence interval for hair loss.
Findings: Of the total participants, 17.6% reported experiencing hair loss after receiving the COVID-19 vaccine. This percentage was higher in females (19.4%) compared to the males (15.2%). There was a significant association between the COVID-19 vaccine and hair loss in both males and females. The odds ratio for developing hair loss after receiving the COVID-19 vaccine was 1.34 (95% CI: 1.04-1.73) for females and 1.12 (95% CI: 0.81-1.54) for males.
Conclusion: Hair loss is a rare but possible side effect of COVID-19 vaccination in both males and females, which its prevalence is higher in females than in males. Individuals with certain comorbidities, such as hypertension and diabetes, may be at a higher risk for experiencing hair loss after COVID-19 vaccination.
Instruments & Methods: A cross-sectional descriptive study was conducted with 580 participants aged between 20 to 72 years, consisting of 270 males and 310 females. Machine learning techniques were employed to analyze the data and determine any potential relationship between COVID-19 vaccines and hair loss. A logistic regression analysis was used to assess the odds ratio and 95% confidence interval for hair loss.
Findings: Of the total participants, 17.6% reported experiencing hair loss after receiving the COVID-19 vaccine. This percentage was higher in females (19.4%) compared to the males (15.2%). There was a significant association between the COVID-19 vaccine and hair loss in both males and females. The odds ratio for developing hair loss after receiving the COVID-19 vaccine was 1.34 (95% CI: 1.04-1.73) for females and 1.12 (95% CI: 0.81-1.54) for males.
Conclusion: Hair loss is a rare but possible side effect of COVID-19 vaccination in both males and females, which its prevalence is higher in females than in males. Individuals with certain comorbidities, such as hypertension and diabetes, may be at a higher risk for experiencing hair loss after COVID-19 vaccination.
Keywords: COVID-19 Vaccines [MeSH], Hair Loss [MeSH], Machine Learning [MeSH], Sociodemographic Factors [MeSH], Comorbidity [MeSH]
Article Type: Original Research |
Subject:
Health Care
Received: 2023/04/23 | Accepted: 2023/07/16 | Published: 2023/08/1
Received: 2023/04/23 | Accepted: 2023/07/16 | Published: 2023/08/1
References
1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-60. [Link]
2. World Health Organization. COVID-19 weekly epidemiological update, edition 84 [Internet]. Geneva: World Health Organization; 2022 [cited 2023 Feb 29]. Available from: https://apps.who.int/iris/handle/10665/352608. [Linkvvv]
3. Rossi A, Magri F, Michelini S, Caro G, Di Fraia M, Fortuna MC, et al. Recurrence of alopecia areata after covid-19 vaccination: A report of three cases in Italy. J Cosmet Dermatol. 2021;20(12):3753-7. [Link] [DOI:10.1111/jocd.14581]
4. Yousif NG, Altimimi AN, Al-amran FG, Adrienne J, Al-Fadhel SM, Hussien SR, et al. Hematological changes among Corona virus-19 patients: a longitudinal study. Syst Rev Pharm. 2020;11(5):862-6. [Link]
5. Yousif MG, Sadeq AM, Alfadhel SM, Al-Amran FG, Al-Jumeily D. The effect of Hematological parameters on pregnancy outcome among pregnant women with Corona Virus -19 infection: a prospective cross-sectional study. J Surv Fisheries Sci. 2023;10(3S):1425-35. [Linkvv]
6. World Health Organization. COVID-19 weekly epidemiological update, edition 58 [Internet]. Geneva: World Health Organization; 2021 [cited 2023 Feb 29]. Available from: https://apps.who.int/iris/handle/10665/345456 [Link]
7. Centers for Disease Control and Prevention. Vaccines for COVID-19 [Internet]. Atlanta, US: Centers for Disease Control and Prevention; 2019 [cited 2023 Feb 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html [Link]
8. World Health Organization. Coronavirus disease (COVID-19) [Internet]. Geneva: World Health Organization; 2019 [cited 2023 Feb 24]. Available from: https://www.who.int/health-topics/coronavirus [Link]
9. Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Diss. 2021;80(10):1306-11. [Link] [DOI:10.1136/annrheumdis-2021-220272]
10. Terracina KA, Tan FK. Flare of rheumatoid arthritis after COVID-19 vaccination. Lancet Rheumatol. 2021;3(7):e469-70. [Link] [DOI:10.1016/S2665-9913(21)00108-9]
11. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine. 2007;25(32):5945-57. [Link] [DOI:10.1016/j.vaccine.2007.04.070]
12. Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98(1):115094. [Link] [DOI:10.1016/j.diagmicrobio.2020.115094]
13. Krause PR, Gruber MF. Emergency use authorization of COVID vaccines-safety and efficacy follow-up considerations. N Engl J Med. 2020;383(19):e107. [Link] [DOI:10.1056/NEJMp2031373]
14. Tatar M, Faraji MR, Montazeri Shoorekchali J, Pagán JA, Wilson FA. The role of good governance in the race for global vaccination during the COVID-19 pandemic. Sci Rep. 2021:11:22440. [Link] [DOI:10.1038/s41598-021-01831-0]
15. Lee GM, Romero JR, Bell BP. Postapproval vaccine safety surveillance for COVID-19 vaccines in the US. JAMA. 2020;324(19):1937-8. [Link] [DOI:10.1001/jama.2020.19692]
16. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021;194:245-51. [Link] [DOI:10.1016/j.puhe.2021.02.025]
17. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427-39. [Link] [DOI:10.1007/s12291-021-00968-z]
18. Ortiz-Prado E, Izquierdo-Condoy JS, Fernandez-Naranjo R, Simbaña-Rivera K, Vásconez-González J, Naranjo EPL, et al. A comparative analysis of a self-reported adverse events analysis after receiving one of the available SARS-CoV-2 vaccine schemes in Ecuador. Vaccines. Vaccines (Basel). 2022;10(7):1047. [Link] [DOI:10.3390/vaccines10071047]
19. Arroyo JH, Izquierdo-Condoy JS, Ortiz-Prado E. A case series and literature review of telogen effluvium and alopecia universalis after the administration of a heterologous COVID-19 vaccine scheme. Vaccines (Basel). 2023;11(2):444. [Link] [DOI:10.3390/vaccines11020444]
20. Esen-Salman K, Akın-Çakıcı Ö, Kardeş S, Salman A. Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic: insights from Google trends. Dermatol Ther. 2021;34(2):e14895. [Link] [DOI:10.1111/dth.14895]
21. Gunderson J, Mitchell D, Reid K, Jordan M. COVID-19 information-seeking and prevention behaviors in Florida, April 2020. Prev Chronic Dis. 2021;18:E17. [Link] [DOI:10.5888/pcd18.200575]
22. Gentile P, Garcovich S. The effectiveness of low-level light/laser therapy on hair loss. Facial Plast Surg Aesthet Med. 2021. [Link] [DOI:10.1089/fpsam.2021.0151]
23. Gentile P, Calabrese C, De Angelis B, Dionisi L, Pizzicannella J, Kothari A, et al. Impact of the different preparation methods to obtain autologous non-activated platelet-rich plasma (A-PRP) and activated platelet-rich plasma (AA-PRP) in plastic surgery: wound healing and hair regrowth evaluation. Int. J Mol Sci. 2020:21(2):431. [Link] [DOI:10.3390/ijms21020431]
24. Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. Stem Cells Transl. Med. 2015;4(11):1317-23. [Link] [DOI:10.5966/sctm.2015-0107]
25. Gentile P, Cole JP, Cole MA, Garcovich S, Bielli A, Scioli MG, et al. Evaluation of not-activated and activated PRP in hair loss treatment: role of growth factor and cytokine concentrations obtained by different collection systems. Int J Mol Sci. 2017;18(2):408. [Link] [DOI:10.3390/ijms18020408]
26. Pratt C, King L, Messenger A, Christiano A, Sundberg J. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):17011. [Link] [DOI:10.1038/nrdp.2017.11]
27. Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol. 2013;2013:348546. [Link] [DOI:10.1155/2013/348546]
28. Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179(5):1033-48. [Link] [DOI:10.1111/bjd.16808]
29. Birkett L, Singh P, Mosahebi A, Dhar S. Possible associations between alopecia areata and COVID-19 vaccination and infection. Aesthet Surg J. 2022;42(11):NP699-702. [Link] [DOI:10.1093/asj/sjac165]
30. Chu CH, Cheng YP, Chan JYL. Alopecia areata after vaccination: recurrence with rechallenge. Pediatr Dermatol. 2016;33(3):e218-9. [Link] [DOI:10.1111/pde.12849]
31. Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA. 1997;278(14):1176-8. [Link] [DOI:10.1001/jama.1997.03550140068042]
32. Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID-19 emergency: Psychological implications. Dermatol Ther. 2020;33(4):e13648. [Link] [DOI:10.1111/dth.13648]
33. Ammar AM, Ibrahim IS, Mohamed AN, Elsaie ML. Dermoscopy-assisted prevalence of hair loss after COVID-19 vaccination among an Egyptian population: a cross-sectional study. Ir J Med Sci. 2023;1971:3. [Link] [DOI:10.1007/s11845-023-03493-5]
34. UK Government. Coronavirus (COVID-19) vaccines adverse reactions [Internet]. London: UK Government; 2022 [cited 2023 Feb 10]. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions [Link]
35. Vaccine Adverse Events Reporting System. VAERS data [Internet]. US: VAERS; 2022 [cited 2023 Feb 15]. Available from: https://vaers.hhs.gov/data.html [Link]
36. Alharbi M. Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia. J Family Med Prim Care. 2022;11(10): 6056-60. [Link] [DOI:10.4103/jfmpc.jfmpc_377_22]
37. Scollan ME, Breneman A, Kinariwalla N, Soliman Y, Youssef S, Bordone LA, et al. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:1-5. [Link] [DOI:10.1016/j.jdcr.2021.11.023]
38. Ganjei Z, Yazdan Panah M, Rahmati R, Zari Meidani F, Mosavi A. COVID-19 vaccination and alopecia areata: a case report and literature review. Clin Case Rep. 2022;10(9):e6039. [Link] [DOI:10.1002/ccr3.6039]
39. Essam R, Ehab R, Al-Razzaz R, Khater MW, Moustafa EA. Alopecia areata after ChAdOx1 nCoV-19vaccine (Oxford/AstraZeneca): a potential triggering factor? J Cosmet Dermatol. 2021;20(12):3727-9. [Link] [DOI:10.1111/jocd.14459]
40. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021;384(13):1273-7. [Link] [DOI:10.1056/NEJMc2102131]
41. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-5. [Link] [DOI:10.1038/s41591-020-0869-5]
42. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of Coronavirus (COVID-19) [Internet]. StatPearls Publishing; 2022 [cited 2023 Feb 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/ [Link]
43. Murugan S, Assi S, Alatrany A, Jayabalan M, Liatsis P, Mustafina J, et al. Consumer behavior prediction during Covid-19 pandemic conditions using sentiment analytics. In The International Conference on Data Science and Emerging Technologies. Singapore: Springer Nature Singapore; 2022 Dec 20. pp. 209-21. [Link] [DOI:10.1007/978-981-99-0741-0_15]
44. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020;10(7):806-13. [Link] [DOI:10.1002/alr.22579]
45. Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The incidence and severity of post-vaccination reactions after vaccination against COVID-19. Vaccines (Basel). 2021;9(5):502. [Link] [DOI:10.3390/vaccines9050502]
46. Alsahli W, Almulhim Y, Issa NT. Cross-sectional study to determine the prevalence of telogen effluvium among patients experiencing COVID-19 infection or vaccination in Saudi Arabia and Arabic countries. Eur J Mol Clin Med. 2022;9(7):4663-74. [Link]
47. Jiang Y, Shi Q, Huang Y, Li J, Xie H, Liu F. Relationship between the exercise and severityof androgenic alopecia. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 28 lipiec 2021;46(7):725-30. [Link]
48. Ganjei Z, Dana HF, Ebrahimi-Dehkordi S, Alidoust F, Bahmani K. Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic. Int Immunopharmacol. 2021;101(Pt B):108324. [Link] [DOI:10.1016/j.intimp.2021.108324]
49. Fivenson D. COVID-19: association with rapidly progressive forms of alopecia areata. Int J Dermatol. 2020;60(1):127. [Link] [DOI:10.1111/ijd.15317]
50. Hani Abdalla H, Ebrahim E. Alopecia areata universalis precipitated by SARS-CoV-2 Vaccine: a case report and narrative review. Cureus. 2022;14(8):e27953. [Link] [DOI:10.7759/cureus.27953]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |